Carboplatin dosing in obese women with ovarian cancer

Carboplatin dosing in obese women with ovarian cancer - PubMed

The patients were stratified into three groups: normal weight (BMI<25.0, 50%), overweight (BMI 25-29.9, 32%) and obese (BMI > or = 30.0, 18%).

The patients were stratified into three groups: normal weight (BMI < 25.0, 50%), overweight (BMI 25–29.9, 32%) and obese (BMI ≥ 30.0, 18%). Compared to ...

Carboplatin dosing in obese women with ovarian cancer: A ...

Obese women may therefore receive a sub-therapeutic carboplatin dose. This study assessed the association between BMI and outcome for ovarian cancer patients ...

Impact of obesity on chemotherapy dosing of carboplatin ... - Nature

... weight women compared to overweight and obese women. ... obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.

Impact of obesity on chemotherapy dosing of carboplatin and ...

Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer ... Br J Cancer. 2023 Jun;128(12):2236-2242. doi ...

Oncologic effects of chemotherapy dose capping in overweight and ...

Chemotherapy dose capping in overweight and obese advanced ovarian cancer patients remains controversial in regard to its effect on oncologic outcomes and ...

Carboplatin dosing in obese women with ovarian cancer: a ...

... Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Wright JD, Tian C, Mutch DG, Herzog TJ, Nagao S, Fujiwara K ...

Carboplatin dosing in obese women with ovarian cancer

The patients were stratified into three groups: normal weight (BMI<25.0, 50%), overweight (BMI 25-29.9, 32%) and obese (BMI > or = 30.0, 18%).

Carboplatin Dosing in Overweight and Obese Patients

Low body weight: body mass index (BMI) <18.5 kg/m · Normal/ideal body weight: BMI 18.5-24.9 kg/m · Overweight: BMI 25-29.9 kg/m · Obese class I: BMI 30-34.9 kg/m ...

What is the optimal treatment for obese patients with advanced ...

006) and overall survival (OS; 53 vs 32 months; P = .036). Seventy-eight patients (66.7%) had a BMI of 30-34.9 kg/m2. Within this subset of obese patients ...

Body Mass Index Affects Ovarian Cancer Chemotherapy Dosages

Approximately 30 percent of those women studied were obese (BMI of 30 or greater) and 31 percent were overweight (BMI between 25 and 29); fewer ...

Does body mass index affect progression-free or overall survival in ...

Patients were assigned to one of four categories: underweight (BMI < 18.5), ideal weight (BMI 18.5–24.9), overweight (BMI 25–29.9) or obese (BMI ≥ 30). Results.

Impact of Obesity on Front-Line Carboplatin Dosing and Survival of ...

Women with a BMI ≥ 30 kg/m2 versus <30 kg/m2 were more likely to be underdosed (RDI < 0.85) with frontline carboplatin. Underdosing of ...

Association of decreased carboplatin dosage and obesity in women ...

Results: 68% (n = 23) of patients were obese with a mean BMI of 36 kg/m2. 35% (n = 8) of obese patients versus 0% of normal/overweight patients ...

Medline ® Abstract for Reference 66 of 'Dosing of anticancer agents ...

Obese women were more likely to have received<85% RDI for carboplatin compared to normal weight women (p<0.001). BMI group and RDI of carboplatin and paclitaxel ...

Impact of Chemotherapy Dosing on Ovarian Cancer Survival ...

Optimal che- motherapy dosing in overweight and obese patients with ovarian cancer remains uncertain. This study evaluated the association of ...

Impact of obesity on chemotherapy dosing of carboplatin and ...

Women with a BMI ≥ 30 kg/m2 versus <30 kg/m2 were more likely to be underdosed (RDI < 0.85) with frontline carboplatin. Underdosing of ...

Obese patients | Cancer Australia

Nine studies were identified which included obese patient populations and compared outcomes by BMI or by obesity. In most of the studies, chemotherapy dosing ...

Toxicity and effectiveness of carboplatin in obese or overweight ...

Ekhart C, Rodenhuis S, Schellens JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?.

Body Mass Index Impacts Ovarian Cancer Chemotherapy Dosages

Approximately 30 percent of those women studied were obese (BMI of 30 or greater) and 31 percent were overweight (BMI between 25 and 29); fewer than three ...